AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00550290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Preoperatively
Description: Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
Study NCT01201304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard exposure
Description: Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
Study NCT01201304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced exposure
Description: Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
Study NCT01201304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exposure
Description: Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
Study NCT01201304 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
Study NCT00111436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Enbrel 50 mg once weekly or 50 mg twice weekly
Study NCT01843205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
Study NCT01843205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
Study NCT01843205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Study NCT01799525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnia by reduction of respiratory volume
Description: By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
Study NCT01843205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Study NCT03682055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: EBNA1 inhibitor
Study NCT01067313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer Ultraflux EMiC2
Description: Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
Study NCT01067313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialyzer Ultraflux AV1000S
Description: Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
Study NCT02816476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study NCT02811172 — intervention group
Intervention type: OTHER
Intervention: BEhavior of biomarkers during pregnanCy and lactatiOn
Study NCT03723408 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ClearLine IV (formerly, AirPurge)
Description: Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
Study NCT03064165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
Study NCT03064165 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham block
Description: Injection as for obturator nerve block, but with placebo
Study NCT03064165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Postoperative obturator nerve block
Study NCT03064165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Placebo
Study NCT02245230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin (1-7)
Description: Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
Study NCT02245230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin (1-7)
Description: Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
Study NCT02245230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
Study NCT02245230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
Study NCT02839811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate hypersensitivity to BLC
Description: immediate hypersensitivity to BLC by In vitro diagnosis
Study NCT03386006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Coach for Bariatric Health
Description: Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
Study NCT02193854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
Study NCT02256527 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: compare data
Study NCT02912169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction under local anesthesia
Description: Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
Study NCT02912169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of AD-SVF via IV and Intranasal
Description: IV and Intranasal Infusion of isolated AD-SVF
Study NCT04405843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Oral Product
Description: Ivermectin oral suspension, 6 mg/mL
Study NCT04405843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
Study NCT02398630 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TC Virtual Hysterosalpingography
Description: Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
Study NCT03082807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCDsport
Description: Negative Calorie Diet supplemented with exercise
Study NCT03082807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCDsport
Description: Low-Calorie diet with exercise
Study NCT02204410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Study NCT02204410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD Medication
Study NCT00728663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---
Study NCT00728663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---
Study NCT03708757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation - Group I
Description: Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
Study NCT03708757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Muscle contraction - Group II
Description: and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
Study NCT02264015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, low, film-coated tablets
Study NCT02264015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, high, film-coated tablets
Study NCT02264015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, film-coated tablets
Study NCT02264015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin, film-coated tablets
Study NCT02736396 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: Functional MRI scan to be performed
Study NCT02398630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI Virtual Hysterosalpingography
Description: Magnetic Resonance Imaging Virtual hysterosalpingography
Study NCT02736396 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological tests
Description: Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
Study NCT01487707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Health Worker (VHW) Program
Description: Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
Study NCT01487707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Birth Kit
Description: A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
Study NCT01487707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Folk Media Campaigns
Description: Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
Study NCT03275415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
Study NCT03275415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
Study NCT03048357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Bed
Description: Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
Study NCT03048357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard hospital bed
Description: Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
Study NCT02463318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is used for healthy subjects and multiple sclerosis patients
Study NCT02463318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Hydrogen peroxide is only used for healthy subjects
Study NCT02444936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: Shingles vaccine
Study NCT04538261 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fetal Pillow insertion
Description: Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
Study NCT04538261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Pillow insertion
Description: Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
Study NCT03537092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Film
Description: 2 x 2 vaginal film with no active drug
Study NCT04479007 — intervention group
Intervention type: DEVICE
Intervention: Probe based optical techniques
Description: During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
Study NCT00261794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive remediation (CACR)
Description: 36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
Study NCT00261794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manualized computer control condition (RC).
Description: 36 sessions of a manualized computer control condition.
Study NCT02398630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antimullerian Hormone dosing
Description: Blood Draw for Antimullerian Hormone dosing
Study NCT02398630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transvaginal Echography
Description: Transvaginal Echography for evaluating the female reproductive system
Study NCT01351389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
Study NCT01351389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
Study NCT00381589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 0.03% spray
Study NCT01594346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Tocopherol
Description: 1,000 International Units, two times a day for 36 months
Study NCT01594346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study NCT02136550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
Study NCT03835988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
Study NCT00453323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
Study NCT00453323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
Study NCT00858676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: 50mg acarbose 3 times a day PO. duration: one year
Study NCT01496989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation
Study NCT01496989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (100mcg)
Description: Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
Study NCT01496989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (1000mcg)
Description: Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
Study NCT01496989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection
Study NCT01789892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study NCT02099682 — intervention group
Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole Capsules 15/ OD Tablets
Study NCT02548130 — intervention group
Intervention type: OTHER
Intervention: MELD score
Description: introduction of MELD score
Study NCT02048930 — intervention group
Intervention type: DEVICE
Intervention: Budesonide Easyhaler
Study NCT02048930 — intervention group
Intervention type: DEVICE
Intervention: Budesonide dry powder inhaler
Study NCT00442039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The starting dose of lithium was 300 mg for patients weighing \< 20 kg
Study NCT00442039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability
Study NCT00442039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability.
Study NCT01789892 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT scan
Study NCT01789892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT scan
Study NCT01789892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT scan
Study NCT03245710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: starch
Study NCT03245710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang powder
Description: the Traditional Chinese Medicine Formula Powder Product
Study NCT01470365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01470365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01470365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional CRT